|
|||||
|
|
Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study |
|
| Authors: | Ronnie Aronson MD Juan Frias MD Allison Goldman Amanda Darekar MSc Brett Lauring MD Steven G. Terra PharmD |
| Affiliation: | 1. LMC Diabetes and Endocrinology, East York, Canada;2. National Research Institute, Los Angeles, California;3. Pfizer, Inc., Collegeville, Pennsylvania;4. Pfizer Ltd., Tadworth, UK;5. Merck & Co., Inc., Kenilworth, New Jersey;6. Pfizer, Inc., Andover, Massachusetts |
| Abstract: | |
| Keywords: | ertugliflozin monotherapy SGLT2 inhibitor type 2 diabetes mellitus |